Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

Haotian Chen,Jihao Shi,Yipeng Pan,Zhou Zhang,Hao Fang,Ying Chen,Wendong Chen,Qian Cao

DOI: https://doi.org/10.1007/s12325-019-01150-x

2019-01-01

Advances in Therapy

Abstract:To assess the cost-effectiveness of reimbursing infliximab for moderate-to-severe Crohn’s disease (MS-CD) in China from the perspective of public insurance payers.

What problem does this paper attempt to address?

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

Ji-Hao Shi,Liang Luo,Xiao-Li Chen,Yi-Peng Pan,Zhou Zhang,Hao Fang,Ying Chen,Wen-Dong Chen,Qian Cao

DOI: https://doi.org/10.3748/wjg.v26.i41.6455

IF: 5.374

2020-11-07

World Journal of Gastroenterology

Abstract:Infliximab was the first approved biologic treatment for moderate to severe Crohn's disease (MS-CD) in China. However, the cost-effectiveness of infliximab maintenance therapy (IMT) for MS-CD relative to conventional maintenance therapy remained unclarified.To assess the cost-effectiveness of IMT for MS-CD in Chinese patients from the perspective of Chinese public insurance payer.A cohort of MS-CD patients managed in a Chinese tertiary care hospital was created to compare IMT with conventional maintenance therapy (CMT) for clinical outcomes and direct medical costs over a 1-year observation time using conventional regression analyses. A decision-analytic model with the generated evidence was constructed to assess the cost-effectiveness of IMT relative to CMT using reimbursed medical costs.Based on the included 389 patients, IMT was associated with significantly higher disease remission chance [odds ratio: 4.060, = 0.003], lower risk of developing new complications (odds ratio: 0.527, = 0.010), higher utility value for quality of life (coefficient 0.822, = 0.008), and lower total hospital costs related to disease management (coefficient -0.378, = 0.008) than CMT. Base-case cost-effectiveness analysis estimated that IMT could cost Chinese health insurance payers ¥55260 to gain one quality-adjusted life year (QALY). The cost-effectiveness of IMT was mainly driven by the estimate of quality of life, treatment efficacy of maintenance therapy, mortality risk associated with active disease, and unit price of infliximab. The probability that IMT was cost-effective at a willingness-to-pay threshold of three times gross domestic product [2018 Chinese gross domestic product per capita (GDPPC)] was 86.4%.IMT significantly improved real-world health outcomes and cost the Chinese public health insurance payers less than one GDPPC to gain one QALY in Chinese MS-CD patients.

gastroenterology & hepatology
The impact of medication belief on adherence to infliximab in patients with Crohn's disease

Shuyan Li,Yan Ma,Hongling Sun,Zijun Ni,Shurong Hu,Yan Chen,Meijuan Lan

DOI: https://doi.org/10.3389/fphar.2023.1185026

IF: 5.6

2023-01-01

Frontiers in Pharmacology

Abstract:Objective: Crohn's disease (CD) is an incurable chronic disease that requires long-term treatment. As an anti-tumor necrosis factor (TNF) agent, Infliximab (IFX) is widely used in the treatment of Crohn's disease, while the adherence is not high. The purpose of this study was to investigate the adherence to IFX among CD patients in China and evaluate the association between medication belief and IFX adherence.Methods: Demographic data, clinical information and patients' medication beliefs were collected using an online questionnaire and reviewing electronic medical records (EMRs). The Beliefs about Medicines Questionnaire (BMQ)-specific was used to assess medication beliefs which contains the BMQ-specific concern score and the BMQ-specific necessity score. An evaluation of adherence factors was conducted using univariate and multidimensional logistic regression analyses.Results: In all, 166 CD patients responded the online questionnaire among which 77 (46.39%) patients had high adherence. The BMQ-specific concern score in patients in low adherence was 30.00 and in high adherence patients was 27.50, and patients with lower BMQ-specific concern score had higher adherence (p = 0.013). The multiple regression analysis showed that the BMQ-specific concern score (OR = 0.940, 95% CI: 0.888-0.996) significantly affected the IFX adherence in CD patients. Otherwise, gender, marital status, time spent on the way (including the waiting time in infusion center) and accommodation to the center were also the influencing factors of adherence.Conclusion: The IFX adherence to CD in China was not high. Medicine concerns may be predictive factor of adherence. Education, the duration of IFX therapy and experience of adverse effects were not significantly associated with IFX adherence. By enhancing knowledge and relieving medicine concerns, we may increase patients' adherence to IFX.
Economic Burden and Health Care Access for Patients with Inflammatory Bowel Diseases in China: Web-Based Survey Study

Qiao Yu,Chunpeng Zhu,Shuyi Feng,Liyi Xu,Shurong Hu,Hao Chen,Hanwen Chen,Sheng Yao,Xiaoying Wang,Yan Chen

DOI: https://doi.org/10.2196/20629

2020-01-01

Abstract:Background The increasing incidence of inflammatory bowel disease (IBD) has imposed heavy financial burdens for Chinese patients; however, data about their financial status and access to health care are still lacking. This information is important for informing patients with IBD about disease treatment budgets and health care strategies. Objective The aim of this study was to evaluate the economic status and medical care access of patients with IBD through the China Crohn’s & Colitis Foundation web-based platform in China. Methods Our study was performed in 14 IBD centers in mainland China between 2018 and 2019 through WeChat. Participants were asked to complete a 64-item web-based questionnaire. Data were collected by the Wenjuanxing survey program. We mainly focused on income and insurance status, medical costs, and access to health care providers. Respondents were stratified by income and the associations of income with medical costs and emergency visit times were analyzed. Results In this study, 3000 patients with IBD, that is, 1922 patients with Crohn disease, 973 patients with ulcerative colitis, and 105 patients with undetermined colitis were included. During the last 12 months, the mean (SD) direct and indirect costs for per patient with IBD were approximately US $11,668.68 ($7944.44) and US $74.90 ($253.60) in China. The average reimbursement ratios for most outpatient and inpatient costs were less than 50%. However, the income of 85.5% (2565/3000) of the patients was less than ¥10,000 (US $1445) per month. Approximately 96.5% (2894/3000) of the patients were covered by health insurance, but only 24.7% (741/3000) of the patients had private commercial insurance, which has higher imbursement ratios. Nearly 98.0% (2954/3000) of the patients worried about their financial situation. Thus, 79.7% (2392/3000) of the patients with IBD tried to save money for health care and even delayed their medical treatments. About half of the respondents (1282/3000, 42.7%) had no primary care provider, and 52.2% (1567/3000) of the patients had to visit the emergency room 1-4 times per year for the treatment of their IBD. Multivariate analysis revealed that lower income (P=.001) and higher transportation (P=.004) and accommodation costs (P=.001) were significantly associated with the increased number of emergency visits of the patients. Conclusions Chinese patients with IBD have enormous financial burdens and difficulties in accessing health care, which have increased their financial anxiety and inevitably influenced their disease outcomes. Early purchase of private insurance, thereby increasing the reimbursement ratio for medical expenses, and developing the use of telemedicine would be effective strategies for saving on health care costs.
REAL-WORLD HEALTH OUTCOMES, ECONOMIC IMPACTS, AND COST EFFECTIVENESS ASSOCIATED WITH INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN A MEDIUM-SIZED CITY OF CHINA

J. Li,Z. Wen,F. Tian,L. Zhang,Y. Luo,L. Deng,J. He,Y. Yang,Y. Chen,H. Zhan,W. Chen

DOI: https://doi.org/10.1016/j.jval.2016.03.1157

IF: 5.156

2016-01-01

Value in Health

Abstract:To compare infliximab versus disease modified anti-rheumatic drugs (DMARD) for disease activity, quality of life, economic impacts, and cost-effectiveness in Chinese patients with rheumatoid arthritis (RA) in a medium-sized city of China. A prospective cohort study followed up RA patients receiving infliximab (33 patients) or DMARD (31 patients) for disease activity (DAS28), quality of life (EQ-5D-3L), and direct medical costs at a tertiary hospital in Zhuzhou, a medium-sized city in the central south of China. The data from this study were used to develop a Markov model-based decision analytic model comparing Infliximab versus DMARD for the cost-effectiveness from the perspective of China health care system. The base case incremental cost-effectiveness ratio (ICER) per gained quality-adjusted life years (QALY) was divided by the forecasted 2015 China gross domestic products per capita (GDPPC) for the comparison with the world health organization (WHO) cost-effectiveness threshold. Probabilistic sensitivity analysis (PSA) was performed to confirm the robustness of base case analysis. One-year follow-up of these patients observed significantly reduced DAS28 (coefficient -2.055, p<0.001), improved quality of life (coefficient 0.294, p<0.001), and increased direct medical costs (coefficient 1.399, p<0.001) associated with infliximab treatment when compared to DMARD after adjusting patient baseline characteristics. The base case ICER per gained QALY associated with infliximab relative to DMARD was 1.620 GDPPC. The 95% credible interval of ICER per gained QALY associated with infliximab (0.455 to 2.866 GDPPC) was below the WHO cost-effectiveness threshold. When compared to DMARD, infliximab significantly reduced disease severity and improved quality of life in Chinese patients with RA living in a medium-sized city of China. Infliximab was cost-effective when compared to DMARD in Chinese patients with RA.
[A Comparative Study of Induction of Remission and Cost-Effectiveness of Enteral Nutrition Versus Infliximab in Moderate-to-severe Crohn's Disease].

Wei-ming Zhu,Lu-gen Zuo,Yi Li,Lei Cao,Wei Zhang,Yun-fei Gu,Ming Xu,Ning Li,Jie-shou Li

DOI: https://doi.org/10.3760/cma.j.issn.0578-1426.2013.09.003

2013-01-01

Abstract:OBJECTIVE:To compare the induction of remission and cost-effectiveness of enteral nutrition (EN) and infliximab (IFX) in moderate-to-severe active Crohn's disease(CD).METHODS:Moderate-to-severe active CD patients were divided into IFX group and EN group. Remission rate, time to remission and treatment cost were compared between the two groups. Clinical remission was defined as Crohn's disease activity index (CDAI) < 150. The quality of life was evaluated by inflammatory bowel disease questionnaire of quality of life (IBDQ).RESULTS:A total of 100 patients were analyzed, including 48 patients in IFX group and 52 patients in EN group. IFX group had higher remission rate [87.5% (42/48) vs 67.3% (35/52) , P = 0.017] and shorter time to remission [(11.00 ± 8.35) days vs (33.94 ± 14.60) days, P < 0.001] than EN group. Treatment costs before remission were similar in two groups (P = 0.351) . The increase of IBDQ scores before and after treatment in IFX group was much higher than that of EN group (42.74 ± 27.50 vs 7.57 ± 22.77, P < 0.001) . Similarly, patients in EN group had greater increase of body mass index (BMI) than that of IFX group [(1.32 ± 0.29)kg/m(2) vs (0.51 ± 0.07) kg/m(2), P < 0.001]. For patients with CDAI < 280, remission rate was not significantly different [85.7% (24/28) vs 81.8% (18/22) , P = 0.718] between the two groups, while treatment cost in EN group was less than that of IFX group [(16.1 ± 5.9)×10(3) RMB vs (22.9 ± 11.9)×10(3) RMB, P = 0.021].CONCLUSIONS:For patients with severe CD (CDAI ≥ 280), IFX has higher remission rate, shorter time to remission and comparable treatment cost than EN. But for patients with CDAI < 280, EN group has comparable remission rate to IFX group with lower cost.
Infliximab For The Treatment Of Crohn'S Disease: Efficacy And Safety In A Chinese Single-Center Retrospective Study

Youlian Zhou,Hanchang He,Pu Wang,Ting Zhang,Minyi Lin,Hong Wang,Yuqiang Nie,Ye Chen

DOI: https://doi.org/10.1097/MEG.0000000000000447

2015-01-01

European Journal of Gastroenterology & Hepatology

Abstract:Background and aim Information describing the efficacy and safety of infliximab (IFX) for Crohn's disease (CD) in China is limited. The aim of this study was to report response rates, relapse rates after IFX-induced remission, and adverse events, and identify factors associated with relapse in a cohort of CD patients treated with IFX in a Chinese center.Patients and methods Clinical data of CD patients treated with two or more infusions of IFX from July 2010 to February 2013 at Nanfang Hospital (Guangzhou, China) were retrieved and analyzed retrospectively. Primary measurements were clinical response rate and relapse rate during 30 weeks of follow-up. Overall adverse events and risk factors related to IFX were evaluated.Results A total of 70 CD patients were finally included. The clinical response rate was 98.6% at week 2, 97% at week 6, 92.5% at week 14, 84.9% at week 22, and 84.1% at week 30. The remission rate was 55.7% at week 2, 94% at week 6, 92.5% at week 14, 82.7% at week 22, and 77.3% at week 30. Relapse began following the third infusion. The relapse rate was 3.23% at week 6, 6.12% at week 14, 10.53% at week 22, and 8.82% at week 30. Adverse events related to IFX occurred in 32.6% of patients; most were mild and transient. Univariate analysis showed that sex was a significant predictor of clinical relapse.Conclusion IFX is an effective and safe treatment for CD in Chinese patients. Sex may be an independent predictor of relapse. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions Through Balancing Abnormal Immune Response in Gut Mucosa

Lijuan Yu,Xuehua Yang,Lu Xia,Jie Zhong,Wensong Ge,Jianxin Wu,Hongchun Liu,Fei Liu,Zhanju Liu

DOI: https://doi.org/10.1155/2015/793764

2015-01-01

Mediators of Inflammation

Abstract:This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn’s disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn’s disease activity index (CDAI) < 150. Clinical response was assessed by a decrease in CDAI ≥ 70, and the failure as a CDAI was not significantly changed or increased. Ten weeks after therapy, 61 (57.5%) patients achieved clinical remission, 17 (16.0%) had clinical response, and the remaining 28 (26.4%) were failed. In remission group, significant changes were observed in CDAI, the Simple Endoscopic Score for Crohn’s Disease (SES-CD), and serum indexes. Patients with short disease duration (22.2 ± 23.2 months) and luminal lesions showed better effects compared to those with long disease duration (71.0 ± 58.2 months) or stricturing and penetrating lesions. IFX markedly downregulated Th1/Th17-mediated immune response but promoted IL-25 production in intestinal mucosa from remission group. No serious adverse events occurred to terminate treatment. Taken together, our studies demonstrated that IFX is efficacious and safe in inducing clinical remission, promoting mucosal healing, and downregulating Th1/Th17-mediated immune response in short course CD patients with luminal lesions.
Different Therapeutic Approaches on Quality of Life in Patients with Inflammatory Bowel Disease

Junjie Xu,Hui Lin,Xu Feng,Minyue Tang,Jun Shen,Zhihua Ran

DOI: https://doi.org/10.1186/s12876-014-0199-5

2014-01-01

BMC Gastroenterology

Abstract:Background: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated.Methods: Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment.Results: MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048).Conclusions: MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD.
Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China

Bin Wu,Alisa Wilson,Fang-fang Wang,Su-li Wang,Daniel J. Wallace,Michael H. Weisman,Liang-jing Lu

DOI: https://doi.org/10.1371/journal.pone.0047373

IF: 3.7

2012-01-01

PLoS ONE

Abstract:Background: To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society.Methodology/Principal Findings: A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and rituximab produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for etanercept, infliximab, and adalimumab without rituximab were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for etanercept, infliximab, and adalimumab with rituximab. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, infliximab and rituximab could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis.Conclusions/Significance: tDMARD was the most cost-effective option in the Chinese healthcare setting. In some relatively developed regions in China, infliximab and rituximab may be a favorable cost-effective alternative for moderate to severe RA.
Infliximab for the Treatment of Crohn’s Disease

Youlian Zhou,Hanchang He,Pu Wang,Ting Zhang,Minyi Lin,Hong Wang,Yuqiang Nie,Ye Chen

DOI: https://doi.org/10.1097/meg.0000000000000447

2015-01-01

Abstract:Information describing the efficacy and safety of infliximab (IFX) for Crohn's disease (CD) in China is limited. The aim of this study was to report response rates, relapse rates after IFX-induced remission, and adverse events, and identify factors associated with relapse in a cohort of CD patients treated with IFX in a Chinese center.Clinical data of CD patients treated with two or more infusions of IFX from July 2010 to February 2013 at Nanfang Hospital (Guangzhou, China) were retrieved and analyzed retrospectively. Primary measurements were clinical response rate and relapse rate during 30 weeks of follow-up. Overall adverse events and risk factors related to IFX were evaluated.A total of 70 CD patients were finally included. The clinical response rate was 98.6% at week 2, 97% at week 6, 92.5% at week 14, 84.9% at week 22, and 84.1% at week 30. The remission rate was 55.7% at week 2, 94% at week 6, 92.5% at week 14, 82.7% at week 22, and 77.3% at week 30. Relapse began following the third infusion. The relapse rate was 3.23% at week 6, 6.12% at week 14, 10.53% at week 22, and 8.82% at week 30. Adverse events related to IFX occurred in 32.6% of patients; most were mild and transient. Univariate analysis showed that sex was a significant predictor of clinical relapse.IFX is an effective and safe treatment for CD in Chinese patients. Sex may be an independent predictor of relapse.
PGI6 DISEASE BURDEN OF MODERATE TO SEVERE CROHN'S DISEASE UNDER CURRENT TREATMENT PATTERN IN CHINA

C. Ying,L. Yan,H. Zhan,Y. Chen,W. Chen

DOI: https://doi.org/10.1016/j.vhri.2020.07.224

2020-01-01

Value in Health Regional Issues

Abstract:To estimate the disease burden of moderate to severe Crohn's disease (MS-CD) under current treatment pattern in China. A decision-analytic model was constructed to simulate the Chinese patients with MS-CD and the age and gender-matched Chinese general population over lifetime time horizon for the differences in overall survival, quality-adjusted life years (QALYs), and lifetime direct medical costs. Literature search was conducted to identify appropriate evidence to estimate the model variables. Base case analysis and sensitivity analysis were conducted for the point estimations and uncertainty of the disease burden of MS-CD. The Chinese MS-CD patients were associated with reduced average overall survival by 2.221 years (42.794 years vs. 45.014 years), reduced average QALY by 7.666 QALY (34.063 QALY vs. 41.768 QALY), and increased average life-time direct medical costs by ¥681,910 (¥893,807 vs. ¥211,897). The reduced QALY associated with MS-CD was highly sensitive to quality of life of disease remission (change: 12.079 QALYs) and active disease (change: 1.009 QALYs),mortality of active disease (change:-1.280 QALYs), and treatment effect of infliximab for induction therapy (change: 0.939) and immunosuppressants for maintenance therapy (change: -0.905). The lifetime direct medical costs associated with MS-CD was highly sensitive to administration of infliximab for maintenance therapy (change: ¥426,022), compliance of infliximab (change: ¥-347,445), drug acquisition costs of infliximab (change: ¥244,187), and hospital costs associated with active disease (change: ¥211,009). The probabilistic sensitivity analysis with 5,000 Monte Carlo simulations estimated the median and 95% credible interval of reduced QALY ( -7.076 QALY, -15.136 to -3.186 QALY) and increased lifetime direct medical costs (¥694,054, ¥363,376 to ¥1,215,003). The disease burden of MS-CD in Chinese patients was mainly characterized with reduced QALY and increased medical costs that were highly sensitive to quality of life, infliximab treatment, and activity disease .
Efficacy of Infliximab in Treatment of Pediatric Crohn's Disease in China

Youyou Luo,Jindan Yu,Hong Zhao,Kerong Peng,Jingan Lou,Ming Ma,Jie Chen

DOI: https://doi.org/10.3760/cma.j.issn.0578-1310.2014.09.010

2014-01-01

Abstract:OBJECTIVE:To investigate the efficacy of infliximab versus corticosteroids in achieving clinical remission in pediatric patients with Crohn's disease in China. METHOD:Data of all newly diagnosed active Crohn's disease pediatric cases seen from June 2009 to December 2013 in Children's Hospital, Zhejiang University School of Medicine were retrospectively recorded and reviewed. INCLUSION CRITERIA:the age of the children was less than 18 years; pediatric Crohn's disease activity index (PCDAI) was more than 10; infliximab or corticosteroids were used for inducing remission; infliximab, immunosuppressive medications or mesalamine was prescribed for maintaining remission. Patients in steroids group were followed up for more than 1 year. The enrolled patients were divided into two groups: infliximab group and steroids group. Clinical data, laboratory findings and side effects of the medications were collected at week 2, 4, 12, 24 and 48. PCDAI and Crohn's disease endoscopic index score (CDEIS) were calculated. Clinical response rate, clinical remission rate, relapse rate, mucosal healing and growth were evaluated. RESULT:Eleven children received infliximab therapy and 11 subjects received corticosteroids. In Infliximab group, 6, 5 and 7 patients were in clinical remission at week 2, 4, and 8, while so were 6, 9, and 9 patients in steroids group. The difference was not statistically significant (χ² = 0.00, 3.14, 0.92, P > 0.05). In infliximab group, 8, 8, and 11 patients were in clinical remission at week 2, 4, and 8, so were 8, 9, and 9 patients in steroids group. The difference was not statistically significant (χ² = 0.00,0.26, 2.20, P > 0.05). When compared with data at baseline, significant decreases were observed in the median PCDAI between the two groups at week 2, 4, and 8 (all P < 0.05). But there were no significant differences between two groups at week 2, 4, and 8 (all P > 0.05). At week 12, 24 and 48, 8/11, 7/8, 3/5 cases on infliximab versus 7/11, 9/11, 8/11 cases on steroids maintained remission. There was no significant differences between the two groups (all P > 0.05). In 7 patients and 9 patients remission was successfully induced at week 8. The relapse rate was similar at week 12, 24, and 48 (χ² = 0.83, 0.09, 1.00, all P > 0.05). Height for age Z score in infliximab group was significantly higher than that in steroids group at week 24 (P < 0.05). Body mass index Z score between the two groups at week 8, 24, and 48 were not statistically significant (all P > 0.05). Of the children treated with infliximab, 3 developed side effects. All the children treated with steroids got Cushing's syndrome. CONCLUSION:In children with Crohn's disease, infliximab therapy is as effective as corticosteroids to induce remission.Less side effects were observed with infliximab therapy compared with immunosuppressive medication and mesalamine.
Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

Pochamana Phisalprapa,Chayanis Kositamongkol,Julajak Limsrivilai,Satimai Aniwan,Phunchai Charatcharoenwitthaya,Pises Pisespongsa,Taya Kitiyakara,Suporn Treepongkaruna,Nathorn Chaiyakunapruk

DOI: https://doi.org/10.1080/13696998.2020.1803889

2020-08-13

Journal of Medical Economics

Abstract:This study aimed to conduct a cost-effectiveness analysis of infliximab and its biosimilar compared to conventional therapy in refractory moderate-to-severe Crohn's disease (CD) in Thailand.A Markov model was used to estimate lifetime costs and health benefits of infliximab from a societal perspective. Our analyses consisted of three choices of treatment (conventional therapy, infliximab originator, and biosimilar) and three treatment scenarios (infliximab 2 years and 3 years if relapse, infliximab 2 years and lifelong if relapse, and infliximab lifelong). The input parameters were obtained from the CD registry and systematic literature reviews. The results were reported as incremental cost-effectiveness ratios (ICERs) in 2017 USD per quality-adjusted life year (QALY) gained. The sensitivity analyses were performed to assess the influence of parameter uncertainty. Threshold sensitivity analyses were carried out to determine the optimal drug prices. Finally, budget impact analyses were conducted.None of the scenarios was cost-effective at Thai willingness-to-pay threshold (4,706 USD/QALY gained). The lowest ICER of 30,121 USD/QALY gained was reported in the scenario that included only standard dose of infliximab biosimilar with the maximum of 5-year treatment. The drug prices need to be reduced by at least 72% to allow infliximab biosimilar to be cost-effective. The 5-year budget impact was only 695,958 USD for the current biosimilar price.Infliximab for the treatment of refractory moderate-to-severe CD in Thailand would be cost-effective if the drug prices were significantly decreased. The best value for money strategy was infliximab biosimilar with a restricted duration of treatment.The use of infliximab and its biosimilar in a restricted duration of maximum 5-year is not cost-effective for patients with moderate-to-severe Crohn's disease refractory to conventional therapy, unless their price was lowered around 72–90% in Thailand.The estimated budget impact for adopting infliximab or its biosimilar for such indication has potential financial feasibility. Policy makers may consider cost-effectiveness and budget impact findings as well as other aspects such as rarity of disease as a part of the decision making process.

medicine, general & internal,health care sciences & services
PIH10 COST-EFFECTIVENESS ANALYSIS OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN OSTEOARTHRITIS IN CHINA

X. Sun,X. Hu,X. Zhen,Y. Li,Y. Gu,Z. Zhao,H. Dong

DOI: https://doi.org/10.1016/j.jval.2020.04.406

IF: 5.156

2020-01-01

Value in Health

Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed to patients with osteoarthritis (OA), it was assumed that both cyclooxygenase-2 (COX-2) inhibitor and non-selective NSAIDs have similar efficacy but associated with different rates of adverse events. Imrecoxib was approved by the Chinese Food and Drug Administration (CFDA) in 2011, which is a COX-2 inhibitor. This study is aimed to access the cost-effectiveness of celecoxib, imrecoxib and diclofenac for managing OA in Chinese aged ≥55 years and ≥65 years based on the real-world data from China. The model adopted in this study was an economic model for OA from the National Institute for Health and Care Excellence, and updated with relative risks from the CONDOR data. The effectiveness indicator was quality-adjusted life years (QALYs), and the analysis was conducted in the social terms. Data of cost was updated with Chinese cost, which was collected from the Hospital Information System (HIS) of 170 hospitals in China (Su-value Database). The relative risk of imrecoxib was collected from randomized controlled trials. Different sceneries of treatment durations and baseline ages were set in the analysis. Over a 6-month treatment duration, compared with no treatment, a higher QALYs gained could be found in imrecoxib (0.30), celecoxib (0.27) and diclofenac (0.20). The cost gained per patient was lowest in diclofenac (＄663.38) while highest in imrecoxib (＄912.28). Imrecoxib was a cost-effective option with the ICER of ＄4309 and ＄2489 versus celecoxib and diclofenac, respectively. A similar result could be found in a 12-month and 24-month treatment duration. In Chinese OA patients aged ≥65 years, the ICER was ＄3856 and ＄2738 for imrecoxib versus celecoxib and diclofenac, respectively, over a 6-month treatment duration. With the gross domestic product/capita in Chinese in 2018 was ＄10407, the imrecoxib can be a cost-effective option over different treatment durations in Chinese OA patients.
Literature Review on Pharmacoeconomics Evaluation of Infliximab in the Treatment of Crohn'sDisease

Jiangjiang He,Shanlian Hu,Jingjing Zhu,Yabing Zhang,Ning Yue,Rui Liu

2014-01-01

Abstract:This study focused on the pharmacoeconomicsevaluation of infliximab in the treatment of Crohn's Disease through literature review.Compared to traditional medicines,infliximab is more cost-effectiveness in childern.Combined therapy of infliximab and azathioprine is also more cost-effectiveness than infliximab monotherapy.
Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

Ling-na YE,Jing-jing XIA,Qian CAO

DOI: https://doi.org/10.3760/cma.j.issn.0254-1432.2013.12.012

2013-01-01

Abstract:Objective To evaluate the clinical efficacy and safety of iMliximab (IFX) in the treatment of Crohn's disease (CD).Methods From February 2009 to March 2013,the clinical data of 62 CD patients with IFX treatment were retrospectively analyzed.At week 14th after IFX injection and the end of follow-up of this study (March 2013) were two observation points.At week 14th after IFX injection (three times of IFX injection),C reactive protein (CRP) level,Crohn's disease activity index (CDAI) score and clinical remission were investigated.At the end of follow-up,clinical remission,fistula closure,mucosal healing and side effects were inspected.Normal distribution data were expressed as 2±s,which were compared with t test.Non normal distribution data were expressed as M (QL-QU) and compared with Wilcoxon test.Results Four cases without complete three times of IFX injection and one case lost to follow-up were eliminated.And nine postoperation cases with IFX treatment to prevent recurrence after surgery were excluded.A total of 48 cases of CD in active period were enrolled in this study on efficacy.At week 14th,CRP level of 48 patients [1.9(0.5,5.4) mg/L]decreased compared with that before treatment [28.9(6.4,51.1) mg/L] (Z=-5.468,P＜0.01);CDAI score (87.0±35.8) also decreased compared with that before treatment (245.1±59.1) (t=18.579,P＜0.01).At week 14th,46 patients in active period achieved clinical remission and the remission rate was 95.8％.By the end of follow-up,38 patients were still in remission period and the remission rate was 79.2％.Among 26 patients with anal fistula before IFX treatment,seven cases (26.9％) were completely closed,17 cases (65.4％) was partially closed and two cases was responseless.Fifteen patients were reviewed by colonoscopic examination after more than six times of IFX treatment.The median of simple endoscopic score for Crohn's disease (SES-CD) was 3 (0,5)after treatment,which decreased compared with that before treatment (8(7,9),Z=-3.306,P=0.001).Twenty-two of 48 cases in active period received,step-up strategy and 26 cases received with top-down strategy.At week 14th,20 cases (90.9％) of group with step-up strategy and 26 cases (100.0％) of group with top-down strategy were in remission period.By the end of follow-up,14 cases (63.6％) of group with step-up strategy and 24 cases (92.3％) of group with top down strategy maintained remission.Among 26 cases with anal fistula,two cases without response were treated with step-up strategy and seven cases with complete closure were all with top-down strategy.Among 62 patients,five had side effects,three of whom had acute infusion reaction,one had delayed infusion reaction and the other had anemia.Conclusions IFX had good clinical efficacy in controlling inflammation,inducing clinical remission,promoting fistula closure and mucosal healing in CD patients.For some CD patients with high risk,the initial top-down strategy showed good clinical efficacy.
The Efficacy and Safety of Infliximab in Pediatric Crohn'S Disease in China

Wang Xiongqiong,Xu Chundi,Hu Hui,Xiao Yuan,Yu Yi,Zhang Ting

DOI: https://doi.org/10.1038/ajg.2017.453

2018-01-01

The American Journal of Gastroenterology

Abstract:BACKGROUND: Few studies have examined the efficacy and safety of infliximab (IFX) in pediatric Crohn's disease (CD) in China. This study aimed to investigate the response and remission rate of IFX, as well as the associated adverse events. METHODS: We collected data from CD patients who had received IFX 2 or more times from three hospitals in Shanghai from January 2007 to December 2016. The efficacy of IFX was observed, as well as the adverse events, relapse rate and retreatment efficacy. The overall risk factors related to IFX were also evaluated. RESULTS: Eighty-six patients participated in the study. With treatment, the patients demonstrated improved growth and nutrition indices and decreased disease activity. The clinical response rate was 91.9% and 88.2% at weeks 10 and 34, respectively. The sustained remission rates were 69.8% and 67.6% at weeks 10 and 34, respectively. The mucous healing rate was 19.3% at week 10 and 25.7% at week 34. Finally, 45 patients (66.2%) demonstrated durable responses, and 23 (33.8%) showed complete LOR. Adverse events related to IFX occurred in 55.8% of the patients, including allergic reactions in 17.4% and infections in 41.9%. Univariate analysis showed that a high pediatric clinical disease activity index score prior to IFX administration was a risk factor for IFX LOR. Continuation of concomitant azathioprine beyond induction was a protective factor for durable response. CONCLUSION(S): IFX is an effective treatment for CD in Chinese children; however, adverse events can occur. A comprehensive evaluation must be performed before each IFX infusion.
Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

Jinsui Zhang,Zemin Xia,Wanjie Guo,Xiaoxiao Ren,Fang Liu,Gargi Ratnaparkhi,Amit Pagada,Subhashini Subramanian,Min Hu,Wen Chen

DOI: https://doi.org/10.1007/s13555-023-01041-8

2023-09-24

Dermatology and Therapy

Abstract:This study assessed the cost-effectiveness of secukinumab compared with other biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and Yisaipu [etanercept biosimilar]) for moderate-to-severe plaque psoriasis from the Chinese healthcare system perspective.

dermatology
Preliminary Study on Treatment of Crohn's Disease with Infliximab

FU Mingsheng,LIU Hongchun,CHEN Shiyao

DOI: https://doi.org/10.3969/j.issn.1008-7125.2011.01.008

2011-01-01

Abstract:Background:The incidence of Crohn's disease(CD) is increasing in recent years.Infliximab(IFX),an anti-tumor necrosis factor-α antibody,can enhance the healing of mucosal lesions in CD patients.Aims:To investigate the therapeutic effect of IFX on CD.Methods:Sixteen CD inpatients at Shanghai Zhongshan Hospital from July 2008 to June 2009 were enrolled.The severity of CD was evaluated by CDAI score,and the patients were divided into conventional therapy group and IFX group.Patients in the two groups were given mesalazine + prednisone and IFX,respectively.After 8-week treatment,CDAI score,WBC,ESR,CRP and ALB levels were compared between the two groups.Results:Eleven mild active CD patients received conventional therapy,while 5 moderate active CD patients were given IFX.All the patients attained clinical remission,however,2 mild active patients with anal fistula turned to IFX after failure of conventional therapy and remission was then attained.After treatment,CDAI score,ESR and CRP levels were improved in both two groups(P<0.05),however,the lowering of CDAI score in IFX group was significantly higher than that in conventional therapy group(P=0.019).Conclusions:IFX is superior to conventional therapy for inducing clinical remission in CD,and can enhance the healing of anal fistula if conventional therapy fails.
Effects of Infliximab Induced Clinical Remission of Active Crohn's Disease on the Level of Interleukin-21 and Interleukin-21 Receptor

HUANG Pei-xin,CHEN Teng-fei,LIU Chang-qin,WU Rui-jin,LIU Zhan-ju

DOI: https://doi.org/10.3760/cma.j.issn.0254-1432.2012.09.015

2012-01-01

Abstract:Objective To investigate the changes of interleukin-21 (IL 21) and interleukin-21 receptor (IL 21R) expression level in Crohn's disease (CD) patients before and after accepted infliximab (IFX) treatment.Methods From June 2009 to July 2011,twenty-two CD patients met the research criteria were recruited at Tenth People's Hospital of Tongji University.Patients were treated with infliximab at weeks 0,2,6,and 16 healthy individuals were set as healthy control group at same time.Peripheral blood of healthy control group was taken at regular physical examination and blood of CD patients was taken before treatment and 10 weeks after treatment,intestinal mucosa biopsy samples were taken under colon endoscopy examination.The changes of Crohn's disease activity index (CDAI),erythrocyte sedimentation rate (ESR),C-reactive protein (CRP) in CD patients were observed.The change of IL-21R in peripheral blood CD4+ T lymphocytes was detected by flow cytometry.The change of IL-21 expression at mRNA level in intestinal mucosa was determined by realtime quantitative polymerase chain reaction (PCR).The data were analyzed by t test.Results Before treatment,the level of IL21R in peripheral blood CD4+ T lymphocytes of CD patients (12.25％±3.25％) and the expression of IL-21 at mRNA level in inflamed intestinal mucosa (1.38±0.32) were both significantly higher than those of healthy controls (4.25 ％ ± 1.41％,0.44±0.18),the differences were statistically significant (F=15.88,6.75 ; both P＜0.05).At 10th week,the level of IL-21R in peripheral blood CD4+ T lymphocytes of CD patients (8.12％ ± 2.05％) and the expression of IL-21 at mRNA level in intestinal mucosa (0.77 ± 0.24) were both significantly lower than those before treatment,the differences were statistically significant ( t=4.880,8.019; both P＜0.01).Before treatment,ESR,CRP and CDAI of CD patients was (46.8±11.4) mm/1 h,(52.4±11.5) mg/L and 319±74,which was (23.5±9.0) mm/1 h,(11.6±4.6) mg/L and 113±42 after treatment,the differences were statistically significant (t=9.485,16.458,11.100; all P＜0.05).Conclusion The IL-21 expression of active CD patients decreases after IFX treatment,which indicates that IL-21 may involve in IFX induced clinical remission of active CD.

Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

The impact of medication belief on adherence to infliximab in patients with Crohn's disease

Economic Burden and Health Care Access for Patients with Inflammatory Bowel Diseases in China: Web-Based Survey Study

REAL-WORLD HEALTH OUTCOMES, ECONOMIC IMPACTS, AND COST EFFECTIVENESS ASSOCIATED WITH INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN A MEDIUM-SIZED CITY OF CHINA

[A Comparative Study of Induction of Remission and Cost-Effectiveness of Enteral Nutrition Versus Infliximab in Moderate-to-severe Crohn's Disease].

Infliximab For The Treatment Of Crohn'S Disease: Efficacy And Safety In A Chinese Single-Center Retrospective Study

Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions Through Balancing Abnormal Immune Response in Gut Mucosa

Different Therapeutic Approaches on Quality of Life in Patients with Inflammatory Bowel Disease

Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China

Infliximab for the Treatment of Crohn’s Disease

PGI6 DISEASE BURDEN OF MODERATE TO SEVERE CROHN'S DISEASE UNDER CURRENT TREATMENT PATTERN IN CHINA

Efficacy of Infliximab in Treatment of Pediatric Crohn's Disease in China

Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

PIH10 COST-EFFECTIVENESS ANALYSIS OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN OSTEOARTHRITIS IN CHINA

Literature Review on Pharmacoeconomics Evaluation of Infliximab in the Treatment of Crohn'sDisease

Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

The Efficacy and Safety of Infliximab in Pediatric Crohn'S Disease in China

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

Preliminary Study on Treatment of Crohn's Disease with Infliximab

Effects of Infliximab Induced Clinical Remission of Active Crohn's Disease on the Level of Interleukin-21 and Interleukin-21 Receptor